Suppr超能文献

通过表达针对WT1的转基因T细胞受体、针对GM-CSF受体的嵌合抗原受体、针对CD33的双特异性T细胞衔接器以及tEGFR自杀基因系统的五基因工程化T细胞靶向急性髓系白血病。

Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system.

作者信息

Šmilauerová Kristýna, Štach Martin, Mucha Martin, Vaníková Šárka, Rychlá Jana, Otáhal Pavel

机构信息

Institute of Hematology and Blood Transfusion, Department of Immunotherapy, Prague, Czechia.

Faculty of Natural Sciences, Charles University, Prague, Czechia.

出版信息

Immunother Adv. 2025 Jun 11;5(1):ltaf022. doi: 10.1093/immadv/ltaf022. eCollection 2025.

Abstract

BACKGROUND

Cancer immunotherapy with transgenic T-cell receptor-engineered T cells (TCR-T) enables the targeting of intracellular tumor-specific antigens; in contrast, chimeric antigen receptor-modified T cells (CAR-T) mediate tumor cell killing via the recognition of surface antigens. In the case of acute myeloid leukemia, the lack of leukemia-specific surface antigens limits the efficacy of CAR-T cells; therefore, TCR-T cells may represent a more targeted immunotherapy approach. However, the tumor immunosuppressive environment eliminates the best-functioning, high-avidity TCR-T cells, thus creating a need for novel, enhanced TCR-T cells.

METHODS

The piggyBac transposon vector used for gene modification of T cells expresses a T-cell receptor specific to the WT1 tumour antigen, an NFAT promoter-regulated CAR specific to GM-CSF receptor, a CD3xCD33 bispecific T-cell engager, and a truncated EGFR suicide gene system. The transgenic T cells were generated by electroporation using a single expression vector, and the efficiency of these engineered TCR-T cells was evaluated using models that utilized AML cell lines and primary AML cells.

RESULTS

The NFAT-driven GM-CSF CAR significantly enhances the antileukemic activity of WT1-specific TCR-T cells, which importantly maintain specificity for their HLA/peptide antigenic complex. Next, by inserting the CD3xCD33 bispecific T-cell engager into the transposon vector, both TCR-T cells and recruited non-transfected bystander T cells can efficiently target the CD33 antigen, providing more robust antileukemic effects.

CONCLUSION

The presented strategy, utilizing a single piggyBac transposon vector, enables the complex redirection of T-cell specificity against acute myeloid leukemia by inserting TCR, CAR, BiTE constructs, along with a tEGFR gene suicide system.

摘要

背景

用转基因T细胞受体工程改造的T细胞(TCR-T)进行癌症免疫治疗能够靶向细胞内肿瘤特异性抗原;相比之下,嵌合抗原受体修饰的T细胞(CAR-T)通过识别表面抗原介导肿瘤细胞杀伤。在急性髓系白血病中,缺乏白血病特异性表面抗原限制了CAR-T细胞的疗效;因此,TCR-T细胞可能代表一种更具靶向性的免疫治疗方法。然而,肿瘤免疫抑制环境会清除功能最佳、亲和力高的TCR-T细胞,因此需要新型的、增强型的TCR-T细胞。

方法

用于T细胞基因改造的piggyBac转座子载体表达一种针对WT1肿瘤抗原的T细胞受体、一种由NFAT启动子调控的针对GM-CSF受体的CAR、一种CD3xCD33双特异性T细胞衔接器以及一个截短的EGFR自杀基因系统。通过使用单个表达载体进行电穿孔产生转基因T细胞,并使用利用AML细胞系和原发性AML细胞的模型评估这些工程化TCR-T细胞的效率。

结果

NFAT驱动的GM-CSF CAR显著增强了WT1特异性TCR-T细胞的抗白血病活性,重要的是,这些细胞对其HLA/肽抗原复合物保持特异性。接下来,通过将CD3xCD33双特异性T细胞衔接器插入转座子载体,TCR-T细胞和募集的未转染旁观者T细胞都能有效靶向CD33抗原,从而提供更强有力的抗白血病作用。

结论

所提出的策略利用单个piggyBac转座子载体,通过插入TCR、CAR和双特异性T细胞衔接器构建体以及tEGFR基因自杀系统,能够实现T细胞特异性针对急性髓系白血病的复杂重定向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3c/12306182/5a988fa6bd1c/ltaf022_fig7.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验